{"id":"intravenous-albumin","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypervolemia / fluid overload"},{"rate":null,"effect":"Pulmonary edema"},{"rate":null,"effect":"Allergic reaction / fever"},{"rate":null,"effect":"Hypertension"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Albumin is a naturally occurring plasma protein that acts as a colloid, drawing and retaining fluid in the intravascular space to maintain adequate circulating blood volume and tissue perfusion. It also serves as a carrier protein for various endogenous and exogenous substances, and has antioxidant and anti-inflammatory properties that may reduce organ dysfunction in critical illness.","oneSentence":"Intravenous albumin restores intravascular oncotic pressure and improves plasma volume expansion in hypovolemic or critically ill patients.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:16:53.577Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypovolemic shock or severe hypoalbuminemia in critically ill patients"},{"name":"Plasma volume expansion in acute blood loss or severe burns"},{"name":"Hepatic cirrhosis with ascites and renal dysfunction"}]},"trialDetails":[{"nctId":"NCT06422143","phase":"PHASE3","title":"Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-06-10","conditions":"Non-small Cell Lung Cancer, NSCLC","enrollment":851},{"nctId":"NCT07259317","phase":"PHASE2","title":"Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma","status":"RECRUITING","sponsor":"Corcept Therapeutics","startDate":"2026-01-27","conditions":"Adenocarcinoma, Carcinoma, Pancreatic Ductal","enrollment":60},{"nctId":"NCT06953323","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors","status":"RECRUITING","sponsor":"Wigen Biomedicine Technology (Shanghai) Co., Ltd.","startDate":"2025-07-10","conditions":"Advanced Solid Tumor","enrollment":86},{"nctId":"NCT06312176","phase":"PHASE3","title":"A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-04-14","conditions":"Breast Neoplasms","enrollment":1200},{"nctId":"NCT07060807","phase":"PHASE3","title":"A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-07-21","conditions":"Breast Neoplasms","enrollment":1000},{"nctId":"NCT07173751","phase":"PHASE3","title":"ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2025-10-30","conditions":"Breast Neoplasms","enrollment":558},{"nctId":"NCT07221474","phase":"PHASE2","title":"A Study of V940/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-12-12","conditions":"Squamous Non-small Cell Lung Cancer","enrollment":180},{"nctId":"NCT07491445","phase":"PHASE3","title":"Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma","status":"RECRUITING","sponsor":"Revolution Medicines, Inc.","startDate":"2026-03-09","conditions":"Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC","enrollment":900},{"nctId":"NCT04476901","phase":"PHASE2","title":"Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy","status":"RECRUITING","sponsor":"Joshua M Hare","startDate":"2021-05-07","conditions":"Non-ischemic Dilated Cardiomyopathy","enrollment":136},{"nctId":"NCT07483554","phase":"PHASE2","title":"IBI343 in Combination Therapy for Advanced Malignant Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2026-03-25","conditions":"CLDN18.2 Positive, Gastric/Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma","enrollment":389},{"nctId":"NCT05852691","phase":"PHASE2","title":"A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-07-18","conditions":"Breast Cancer","enrollment":83},{"nctId":"NCT06767527","phase":"PHASE3","title":"AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer","status":"RECRUITING","sponsor":"Akeso","startDate":"2025-02-07","conditions":"Triple-Negative Breast Cancer (TNBC)","enrollment":416},{"nctId":"NCT03816163","phase":"PHASE2","title":"A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2019-03-15","conditions":"Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma","enrollment":393},{"nctId":"NCT04895358","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-06-18","conditions":"Breast Neoplasms","enrollment":340},{"nctId":"NCT05491512","phase":"PHASE2","title":"A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2022-08-04","conditions":"HPV, Throat Cancer, Oropharyngeal Carcinoma","enrollment":121},{"nctId":"NCT07457359","phase":"PHASE2","title":"Neoadjuvant Toripalimab Plus SBRT for Chemo-Resistant Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-01-04","conditions":"TNBC, Triple Negative Breast Cancer","enrollment":18},{"nctId":"NCT06953999","phase":"PHASE3","title":"A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer","status":"RECRUITING","sponsor":"Akeso","startDate":"2025-06-11","conditions":"Pancreatic Cancer","enrollment":999},{"nctId":"NCT07449364","phase":"NA","title":"Allogeneic Human Mesenchymal Stem Cell Infusion for Frailty Patient","status":"COMPLETED","sponsor":"Daewoong Group Indonesia","startDate":"2025-03-24","conditions":"Frailty in Older Adults","enrollment":10},{"nctId":"NCT04494425","phase":"PHASE3","title":"Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-07-24","conditions":"Advanced or Metastatic Breast Cancer","enrollment":866},{"nctId":"NCT07444541","phase":"PHASE1, PHASE2","title":"ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Anova Innovation Limited","startDate":"2026-03","conditions":"Pancreatic Cancer","enrollment":84},{"nctId":"NCT05382559","phase":"PHASE1","title":"A Study of ASP3082 in Adults With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Astellas Pharma Inc","startDate":"2022-06-08","conditions":"Solid Tumor","enrollment":681},{"nctId":"NCT07437898","phase":"PHASE2","title":"Neoadjuvant Adebrelimab Plus Chemotherapy for Esophageal Cancer: A Clinical Study","status":"RECRUITING","sponsor":"The Affiliated Hospital of Putian University","startDate":"2024-09-03","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":42},{"nctId":"NCT07432594","phase":"PHASE2","title":"Neoadjuvant Aitua (PD-1/CTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous Ovarian Cancer","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-03-01","conditions":"High-grade Serous Ovarian Cancer (HGSOC), Fallopian Tube Cancers, Primary Peritoneal Cancer","enrollment":82},{"nctId":"NCT07432087","phase":"PHASE3","title":"Camrelizumab Combined With EGFR Monoclonal Antibody or Chemotherapy for Perioperative Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Yue He, MD","startDate":"2026-02-01","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":246},{"nctId":"NCT03976362","phase":"PHASE3","title":"A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-06-28","conditions":"Carcinoma, Squamous Cell, Non-small-cell Lung","enrollment":851},{"nctId":"NCT06996782","phase":"PHASE1, PHASE2","title":"A Platform Study in Non-Small Cell Lung Cancer (NSCLC)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-11-24","conditions":"Advanced or Metastatic Non-small Cell Lung Cancer","enrollment":152},{"nctId":"NCT06904378","phase":"PHASE1, PHASE2","title":"ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2026-03-31","conditions":"Metastatic Pancreatic Ductal Adenocarcinoma","enrollment":61},{"nctId":"NCT05722938","phase":"PHASE3","title":"Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)","status":"RECRUITING","sponsor":"Biotest","startDate":"2023-09-09","conditions":"Community-acquired Pneumonia","enrollment":590},{"nctId":"NCT07410975","phase":"PHASE2","title":"Efficacy of Anti-CTLA-4 Antibody Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2026-01-10","conditions":"NSCLC Stage II, NSCLC Stage III","enrollment":54},{"nctId":"NCT07240766","phase":"PHASE2","title":"HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation","status":"RECRUITING","sponsor":"Zhejiang University","startDate":"2026-02-15","conditions":"Borderline Resectable Pancreatic Adenocarcinoma","enrollment":40},{"nctId":"NCT07281976","phase":"PHASE1, PHASE2","title":"A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"Nanjing Leads Biolabs Co.,Ltd","startDate":"2026-01-27","conditions":"Triple Negative Breast Cancer","enrollment":220},{"nctId":"NCT06752811","phase":"PHASE3","title":"Polymeric Micellar Paclitaxel for Metastatic Pancreatic Cancer","status":"RECRUITING","sponsor":"Shanghai Yizhong Pharmaceutical Co., Ltd.","startDate":"2025-02-05","conditions":"Pancreatic Cancer Metastatic","enrollment":416},{"nctId":"NCT05208242","phase":"PHASE2, PHASE3","title":"Strong Albumin Solutions in Patients With Septic Shock","status":"COMPLETED","sponsor":"Manchester University NHS Foundation Trust","startDate":"2023-11-10","conditions":"Sepsis, Septic Shock, Shock, Toxic","enrollment":47},{"nctId":"NCT05226598","phase":"PHASE3","title":"Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-03-24","conditions":"Metastatic Non-Small Cell Lung Cancer","enrollment":739},{"nctId":"NCT07384416","phase":"PHASE2","title":"Single-Arm Trial of QL1706, Lenvatinib, and Nab-Paclitaxel for Advanced Refractory Penile Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-02-10","conditions":"Penile Cancer","enrollment":47},{"nctId":"NCT07383922","phase":"PHASE3","title":"A Study of FG-M108+Chemotherapy vs Placebo+Chemotherapy in Claudin18.2-positive Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"FutureGen Biopharmaceutical (Beijing) Co., Ltd","startDate":"2026-02-28","conditions":"Pancreatic Cancer","enrollment":524},{"nctId":"NCT07385001","phase":"PHASE1, PHASE2","title":"A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC","status":"RECRUITING","sponsor":"Tang-Du Hospital","startDate":"2026-01-28","conditions":"Esophageal Squamous Cell Carcinoma, Ivonescimab, Neoadjuvant","enrollment":45},{"nctId":"NCT04999969","phase":"PHASE2","title":"Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-12-10","conditions":"Locally Advanced or Metastatic Solid Tumours","enrollment":126},{"nctId":"NCT05867121","phase":"PHASE1","title":"A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genentech, Inc.","startDate":"2023-10-02","conditions":"Non-small Cell Lung Cancer, Gastric Cancer, Pancreatic Ductal Adenocarcinoma","enrollment":102},{"nctId":"NCT07374003","phase":"PHASE2","title":"Ipromlimab and Tuvonralimab Combined With Albumin-Bound Paclitaxel and Nedaplatin as Neoadjuvant Therapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-12-17","conditions":"Locally Advanced, Resectable","enrollment":62},{"nctId":"NCT07371624","phase":"PHASE1, PHASE2","title":"A Study of the Safety, Tolerability and Preliminary Efficacy of B2065 in Patients With Acute Ischemic Stroke.","status":"RECRUITING","sponsor":"Tasly Pharmaceutical Group Co., Ltd","startDate":"2025-12-31","conditions":"Acute Ischemic Stroke","enrollment":54},{"nctId":"NCT07361991","phase":"PHASE1, PHASE2","title":"IBI363 Plus Bevacizumab With or Without Nab-Paclitaxel for Second-Line Treatment of Advanced Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2026-03","conditions":"Advan'ce'd, Advanced","enrollment":50},{"nctId":"NCT03456063","phase":"PHASE3","title":"A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2018-04-24","conditions":"Non-Small-Cell Lung","enrollment":453},{"nctId":"NCT06957886","phase":"PHASE3","title":"A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2025-05-15","conditions":"HER2-low Breast Cancer","enrollment":566},{"nctId":"NCT07353723","phase":"PHASE2","title":"Nimotuzumab Combined With Toripalimab and Chemotherapy for Locally Advanced Tonsillar Cancer","status":"RECRUITING","sponsor":"Tang-Du Hospital","startDate":"2025-11-15","conditions":"Head & Neck Cancer","enrollment":10},{"nctId":"NCT07348107","phase":"PHASE1","title":"ATRA and SDK002 in Combination With Chemotherapy and Anti-PD-1 Inhibitor in Patients With Advanced Pancreatic Ductal Adenocarcinoma.","status":"NOT_YET_RECRUITING","sponsor":"Daniel Breadner","startDate":"2026-02-15","conditions":"Advanced Pancreatic Ductal Adenocarcinoma","enrollment":10},{"nctId":"NCT05522985","phase":"PHASE2","title":"Neoadjuvant Chemotherapytreatment of Locally Advanced Head and Neck Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2021-11-07","conditions":"Head and Neck Squamous Cell Carcinoma, Neoadjuvant Chemotherapy","enrollment":122},{"nctId":"NCT06654011","phase":"PHASE2","title":"IN10018 With Nab-Paclitaxel and Cadonilimab for Metastatic or Recurrent Gastric-Type Cervical Adenocarcinoma: Phase 2 Trial","status":"RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2025-02-17","conditions":"Cervical Adenocarcinoma, Gastric-type Endocervical Adenocarcinoma","enrollment":25},{"nctId":"NCT04770272","phase":"PHASE2","title":"Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy","status":"TERMINATED","sponsor":"Palleos Healthcare GmbH","startDate":"2021-03-01","conditions":"Triple-negative Breast Cancer","enrollment":442},{"nctId":"NCT07255404","phase":"PHASE2","title":"A Clinical Trial Testing the Safety of BNT327 (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2025-12-04","conditions":"Pancreatic Ductal Adenocarcinoma (PDAC)","enrollment":105},{"nctId":"NCT03265808","phase":"PHASE1, PHASE2","title":"Allogeneic Human Mesenchymal Stem Cell Infusion vs Placebo in Alcohol Use Disorder and Major Depression.","status":"COMPLETED","sponsor":"Ihsan M Salloum, MD, MPH","startDate":"2018-03-18","conditions":"Major Depressive Disorder, Alcohol Use Disorder","enrollment":31},{"nctId":"NCT07328854","phase":"PHASE3","title":"40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Ming-Yuan Chen","startDate":"2025-11-20","conditions":"Nasopharyngeal Carcinoma","enrollment":346},{"nctId":"NCT06132958","phase":"PHASE3","title":"Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-12-06","conditions":"Endometrial Cancer","enrollment":710},{"nctId":"NCT06741644","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"CStone Pharmaceuticals","startDate":"2025-02-24","conditions":"Advanced Solid Tumors","enrollment":660},{"nctId":"NCT06124118","phase":"PHASE1","title":"Tumor Treating Fields for Locally Advanced NSCLC","status":"RECRUITING","sponsor":"University of Utah","startDate":"2024-04-04","conditions":"Non Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT06399289","phase":"PHASE3","title":"Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Chinese Subjects With Hemophilia B Previously Treated With FIX Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"CSL Behring","startDate":"2024-07-28","conditions":"Hemophilia B","enrollment":23},{"nctId":"NCT07318883","phase":"PHASE2, PHASE3","title":"A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous Non-Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2026-03","conditions":"Squamous NSCLC","enrollment":720},{"nctId":"NCT07313878","phase":"NA","title":"Evaluation of Acute and Chronic Nephrotoxicity in Acute Lymphatic Leukemia Patients Using Ultrasound Localization Microscopy","status":"RECRUITING","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2025-11-19","conditions":"Acute Lymphoblastic Leukaemias (ALL), Long Term Follow-Up","enrollment":30},{"nctId":"NCT07235202","phase":"PHASE1, PHASE2","title":"A Study of MR001 Combined With Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) After First-line Therapy","status":"RECRUITING","sponsor":"Shenzhen Majory Biotechnology Co., Ltd.","startDate":"2025-12-24","conditions":"Pancreatic Ductal Adenocarcinoma (PDAC)","enrollment":45},{"nctId":"NCT07312578","phase":"PHASE2","title":"Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy（nCT） in the Treatment of Esophageal Squamous Cell Carcinoma","status":"ENROLLING_BY_INVITATION","sponsor":"Peking University","startDate":"2025-11-01","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":48},{"nctId":"NCT04831320","phase":"PHASE2","title":"Nab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 Inhibitor","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2021-09-28","conditions":"Metastatic Head-and-neck Squamous-cell Carcinoma","enrollment":46},{"nctId":"NCT04148911","phase":"PHASE3","title":"A Study of Atezolizumab Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic PD-L1-Positive Triple-Negative Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2019-12-10","conditions":"Triple-Negative Breast Cancer","enrollment":184},{"nctId":"NCT07302841","phase":"PHASE4","title":"Tunlametinib + AG + Cetuximab β as First-Line Therapy for Advanced Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-01-20","conditions":"Pancreatic Cancer Non-resectable","enrollment":28},{"nctId":"NCT07270874","phase":"PHASE4","title":"Study to Evaluate the Efficacy of Intravenous Administration of Human Albumin Versus Saline Solution in Patients With descompénsate Cirrhosis Grade 1B or Higher Renal Failure","status":"NOT_YET_RECRUITING","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2026-01","conditions":"Decompensated Cirrhosis, AKI - Acute Kidney Injury","enrollment":114},{"nctId":"NCT07286253","phase":"PHASE2","title":"QL1706 Plus Chemotherapy as Neoadjuvant Therapy for Locally Advanced Cervical Cancer: A Phase II Trial","status":"RECRUITING","sponsor":"Affiliated Cancer Hospital & Institute of Guangzhou Medical University","startDate":"2025-10-28","conditions":"Neoadjuvant Treatment for Locally Advanced Cervical Cancer","enrollment":50},{"nctId":"NCT06385925","phase":"PHASE1, PHASE2","title":"A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation","status":"RECRUITING","sponsor":"Tyligand Pharmaceuticals (Suzhou) Limited","startDate":"2024-04-29","conditions":"Malignant Neoplasm","enrollment":440},{"nctId":"NCT06625320","phase":"PHASE3","title":"Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Revolution Medicines, Inc.","startDate":"2024-10-16","conditions":"Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma","enrollment":501},{"nctId":"NCT07267286","phase":"PHASE2","title":"Tirellizumab Combined With TP Neoadjuvant Therapy in the Treatment of Early Oral Squamous Cell Carcinoma （HNC-SYSU-005）","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-12-15","conditions":"HNSCC, PD-1","enrollment":60},{"nctId":"NCT07259590","phase":"PHASE1, PHASE2","title":"A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation","status":"RECRUITING","sponsor":"Genfleet Therapeutics (Shanghai) Inc.","startDate":"2025-10-21","conditions":"Advanced Solid Tumors Cancer, PDAC, CRC (Colorectal Cancer)","enrollment":126},{"nctId":"NCT07241936","phase":"PHASE1, PHASE2","title":"A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors","status":"RECRUITING","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2025-11-13","conditions":"Advanced Solid Tumors","enrollment":444},{"nctId":"NCT07244965","phase":"PHASE2","title":"Neoadjuvant Ivonescimab Plus Chemotherapy Followed by Concurrent Chemoradiotherapy in High-Risk Locally Advanced Cervical Cancer","status":"NOT_YET_RECRUITING","sponsor":"Women's Hospital School Of Medicine Zhejiang University","startDate":"2025-12-01","conditions":"LOCALLY ADVANCED CERVICAL CANCERS","enrollment":42},{"nctId":"NCT04701034","phase":"PHASE2","title":"Intravenous Immunoglobulin and Prednisolone for RPL After ART.","status":"COMPLETED","sponsor":"Aalborg University Hospital","startDate":"2021-01-28","conditions":"Habitual Abortion, Recurrent Pregnancy Loss, Fertility Disorders","enrollment":80},{"nctId":"NCT05631899","phase":"PHASE1","title":"CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2023-04-03","conditions":"Solid Tumor, Adult, EphA2 Overexpression, KRAS G12V","enrollment":9},{"nctId":"NCT07212582","phase":"PHASE3","title":"Human Albumin for Resuscitation in Surgical Septic Shock: A Randomized Controlled Trial (ALBUS Study)","status":"NOT_YET_RECRUITING","sponsor":"Mahidol University","startDate":"2025-12-01","conditions":"Critical Illness, Septic Shock","enrollment":304},{"nctId":"NCT07233850","phase":"PHASE2","title":"A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers","status":"NOT_YET_RECRUITING","sponsor":"Shenyang Sunshine Pharmaceutical Co., LTD.","startDate":"2025-11","conditions":"Gastric/Gastroesophageal Junction Adenocarcinoma, Metastatic Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC)","enrollment":300},{"nctId":"NCT06212752","phase":"PHASE3","title":"A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-06-13","conditions":"Metastatic Non-small Cell Lung Cancer","enrollment":39},{"nctId":"NCT03396445","phase":"PHASE1","title":"Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-02-18","conditions":"Pharmacokinetics, Solid Tumor, Carcinoma, Non-Small-Cell Lung","enrollment":182},{"nctId":"NCT03805789","phase":"PHASE2, PHASE3","title":"The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"CSL Behring","startDate":"2019-03-27","conditions":"Acute-graft-versus-host Disease","enrollment":222},{"nctId":"NCT04958785","phase":"PHASE2","title":"Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2021-12-14","conditions":"Triple-Negative Breast Cancer","enrollment":92},{"nctId":"NCT03520686","phase":"PHASE3","title":"Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2018-05-18","conditions":"Non Small Cell Lung Cancer","enrollment":1538},{"nctId":"NCT04390763","phase":"PHASE2","title":"Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-10-16","conditions":"Metastatic Pancreatic Ductal Adenocarcinoma","enrollment":164},{"nctId":"NCT06425757","phase":"PHASE4","title":"Study on Pharmacokinetics of Single Injection of Ciprofol in Patients With Moderate to Severe Hypoproteinemia","status":"COMPLETED","sponsor":"Xie Kangjie","startDate":"2024-04-04","conditions":"Hypoproteinemia, Pharmacokinetics, Ciprofol","enrollment":36},{"nctId":"NCT04257448","phase":"PHASE1, PHASE2","title":"Safety and Tolerance of Epigenetic and Immunomodulating Drugs Combined With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"GWT-TUD GmbH","startDate":"2020-05-25","conditions":"Pancreas Cancer, Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma","enrollment":75},{"nctId":"NCT05867602","phase":"PHASE2","title":"High Dose Albumin in Refractory Ascites","status":"RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2019-03-25","conditions":"Ascites","enrollment":100},{"nctId":"NCT06770439","phase":"PHASE2","title":"IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"Zhejiang University","startDate":"2025-04-18","conditions":"Advanced Pancreatic Cancers","enrollment":64},{"nctId":"NCT06770452","phase":"PHASE2","title":"HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients","status":"RECRUITING","sponsor":"Zhejiang University","startDate":"2025-03-25","conditions":"Metastatic Pancreatic Carcinoma","enrollment":32},{"nctId":"NCT06942234","phase":"PHASE1, PHASE2","title":"Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer","status":"RECRUITING","sponsor":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","startDate":"2025-06-01","conditions":"Inoperable Locally Advanced HER2-Negative Breast Cancer, Metastatic HER2-Negative Breast Cancer","enrollment":180},{"nctId":"NCT06145308","phase":"PHASE2","title":"Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing","status":"RECRUITING","sponsor":"Peking Union Medical College","startDate":"2023-08-15","conditions":"Salivary Gland Carcinoma, Precision Therapy","enrollment":39},{"nctId":"NCT05722015","phase":"PHASE3","title":"A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-02-14","conditions":"Metastatic Non-small Cell Lung Cancer","enrollment":377},{"nctId":"NCT04869397","phase":"PHASE2","title":"Treatment of Respiratory Complications Associated With COVID-19 Using Umbilical Cord Mesenchymal Stromal Cells","status":"TERMINATED","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2021-06-14","conditions":"Covid19","enrollment":19},{"nctId":"NCT07040644","phase":"PHASE2","title":"A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-09","conditions":"Triple Negative Breast Neoplasms","enrollment":150},{"nctId":"NCT06934473","phase":"NA","title":"Effects of Endogenous GIP on Postprandial Blood Pressure in Healthy Individuals","status":"RECRUITING","sponsor":"University Hospital, Gentofte, Copenhagen","startDate":"2025-05-21","conditions":"Bloodpressure","enrollment":16},{"nctId":"NCT06947291","phase":"PHASE2","title":"Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors","status":"RECRUITING","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2025-06-04","conditions":"Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors","enrollment":350},{"nctId":"NCT02219165","phase":"PHASE2","title":"Efficacy of IntraVenous ImmunoGlobulins in Toxic Shock Syndromes: a Paediatric Pilot Study","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2015-01-08","conditions":"Toxic Shock Syndrome","enrollment":30},{"nctId":"NCT06313970","phase":"PHASE2","title":"First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-06-20","conditions":"Pancreatic Cancer","enrollment":58},{"nctId":"NCT04167514","phase":"PHASE3","title":"Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids Alone","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2020-01-09","conditions":"Graft Versus Host Disease (GVHD)","enrollment":136},{"nctId":"NCT06483737","phase":"NA","title":"Human Albumin Infusion in Liver Cirrhosis and Overt Hepatic Encephalopathy (HACHE)","status":"RECRUITING","sponsor":"General Hospital of Shenyang Military Region","startDate":"2025-06-24","conditions":"Overt Hepatic Encephalopathy","enrollment":174},{"nctId":"NCT07131306","phase":"PHASE2","title":"National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM): Evaluating Mesenchymal Stem Cell Therapy in Non-viral Acute on Chronic Liver Failure (ACLF) Patient- Phase-II Trial","status":"NOT_YET_RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2027-01","conditions":"Acute-On-Chronic Liver Failure","enrollment":100},{"nctId":"NCT07075315","phase":"PHASE3","title":"National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM): Evaluating Mesenchymal Stem-Cell (MSC) Therapy in Non-viral Acute on Chronic Liver Failure (ACLF) Patients - Phase-III Trial","status":"NOT_YET_RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2028-01","conditions":"Acute-On-Chronic Liver Failure","enrollment":100},{"nctId":"NCT06255392","phase":"PHASE3","title":"Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-06-12","conditions":"Fludzoparib" and Anti-angiogenic, HRD-positive/HER2-negative Advanced Breast Cancer","enrollment":200}],"_emaApprovals":[],"_faersSignals":[{"count":5,"reaction":"ACUTE HEPATIC FAILURE"},{"count":5,"reaction":"DRUG INEFFECTIVE FOR UNAPPROVED INDICATION"},{"count":5,"reaction":"RENAL FAILURE ACUTE"},{"count":5,"reaction":"SHOCK HAEMORRHAGIC"}],"_approvalHistory":[],"publicationCount":326,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Intravenous albumin","genericName":"Intravenous albumin","companyName":"Hamilton Health Sciences Corporation","companyId":"hamilton-health-sciences-corporation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Intravenous albumin restores intravascular oncotic pressure and improves plasma volume expansion in hypovolemic or critically ill patients. Used for Hypovolemic shock or severe hypoalbuminemia in critically ill patients, Plasma volume expansion in acute blood loss or severe burns, Hepatic cirrhosis with ascites and renal dysfunction.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}